Glenmark Pharma shares gained 4% to trade at Rs 1,995.60 in Wednesday's session, witnessing a surge in volume. The stock is among the top gainers on the Nifty Midcap 150 index.
The company's consolidated annual revenue for the year-ending March 2025 stood at Rs 13,321.74 Crore, compared to Rs 11,813.10 Crore in the previous year. The net profit for the year-ending March 2025 was Rs 1,047.14 Crore, against a loss of Rs -1,830.85 Crore in the year-ending March 2024. Earnings per share (EPS) for the year-ending March 2025 was Rs 37.11, compared to Rs -53.22 in the year-ending March 2024.
The company’s consolidated quarterly revenue for June 2025 stood at Rs 3,264.44 Crore, up from Rs 3,256.21 Crore in March 2025. The net profit for the quarter was Rs 46.97 Crore, a significant increase from Rs 4.38 Crore in the previous quarter. The EPS for June 2025 was Rs 1.66, compared to Rs 0.16 in March 2025.
Glenmark Pharma Consolidated Financials (Crore)
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 3,244.19 Crore | Rs 3,433.80 Crore | Rs 3,387.55 Crore | Rs 3,256.21 Crore | Rs 3,264.44 Crore |
| Net Profit | Rs 340.24 Crore | Rs 354.49 Crore | Rs 348.03 Crore | Rs 4.38 Crore | Rs 46.97 Crore |
| EPS | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 |
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 10,943.93 Crore | Rs 12,304.90 Crore | Rs 12,990.11 Crore | Rs 11,813.10 Crore | Rs 13,321.74 Crore |
| Net Profit | Rs 970.09 Crore | Rs 993.65 Crore | Rs 377.40 Crore | Rs -1,830.85 Crore | Rs 1,047.14 Crore |
| EPS | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 |
| BVPS | 250.36 | 334.48 | 348.70 | 278.09 | 313.60 |
| ROE | 13.73 | 10.36 | 3.13 | -19.13 | 11.83 |
| Debt to Equity | 0.66 | 0.40 | 0.46 | 0.13 | 0.25 |
The company had announced a final dividend of Rs 2.50 per share (250%) on May 23, 2025, with the effective date being September 15, 2025. The stock split its face value from Rs 2 to Rs 1 on September 10, 2007, and previously from Rs 10 to Rs 2 on October 23, 2003.
Glenmark Pharmaceuticals Limited informed the Exchange regarding a press release dated September 02, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials.
With the stock currently trading at Rs 1,995.60, Glenmark Pharma has shown significant positive movement today.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
